Source:http://linkedlifedata.com/resource/pubmed/id/19793402
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2009-10-19
|
pubmed:abstractText |
Acetylcholine plays a major role in mediating attention processes. We investigated the muscarinic antagonist effect of scopolamine on functional neuro-anatomy of attention and cognition. We assessed 12 healthy volunteers while performing the Attention Network Task on 0.4 mg scopolamine and placebo in a single-blind randomized trial in a 1.5 T magnetic resonance scanner. Neurocognitive measures included verbal learning, verbal memory, verbal fluency, trail making, digit span, a continuous performance task and a planning task (Tower of London). When compared to placebo, scopolamine increased reaction times for conflicting stimulus processing, together with decreasing brain activation in the anterior cingulate cortex (a brain region involved in conflict processing) suggestive of a muscarinic antagonist effect on executive control of attention. Contrary to the notion of a predominantly right-hemispheric lateralization of cognitive processes associated with orienting attention, scopolamine reduced brain activity in left superior and left middle frontal brain areas. Our neuropsychological test data revealed a selective effect of scopolamine on verbal learning and memory while other cognitive domains, such as planning and working memory, were unaffected. These findings are consistent with muscarinic modulation of dopaminergic neurotransmission in frontal attention networks when processing conflicting information.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1469-5111
|
pubmed:author |
pubmed-author:HabelUteU,
pubmed-author:HalfterSarahS,
pubmed-author:KellermannThiloT,
pubmed-author:KircherTiloT,
pubmed-author:RadenbachKatrinK,
pubmed-author:ReskeMartinaM,
pubmed-author:SchallUlrichU,
pubmed-author:ShahNadim JonNJ,
pubmed-author:SheldrickAbigail JAJ,
pubmed-author:ThienelRenateR,
pubmed-author:VossBiancaB
|
pubmed:issnType |
Electronic
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1307-17
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:19793402-Adult,
pubmed-meshheading:19793402-Attention,
pubmed-meshheading:19793402-Cross-Over Studies,
pubmed-meshheading:19793402-Executive Function,
pubmed-meshheading:19793402-Humans,
pubmed-meshheading:19793402-Male,
pubmed-meshheading:19793402-Muscarinic Antagonists,
pubmed-meshheading:19793402-Psychomotor Performance,
pubmed-meshheading:19793402-Reaction Time,
pubmed-meshheading:19793402-Scopolamine Hydrobromide,
pubmed-meshheading:19793402-Single-Blind Method,
pubmed-meshheading:19793402-Young Adult
|
pubmed:year |
2009
|
pubmed:articleTitle |
Muscarinic antagonist effects on executive control of attention.
|
pubmed:affiliation |
Centre for Rural and Remote Mental Health, University of Newcastle, Australia. renate.thienel@newcastle.edu.au
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|